A new trading day began on Tuesday, with ITeos Therapeutics Inc (NASDAQ: ITOS) stock price up 13.44% from the previous day of trading, before settling in for the closing price of $6.92. ITOS’s price has ranged from $4.80 to $18.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 12.04%. Meanwhile, its annual earnings per share averaged -3.58%. With a float of $33.10 million, this company’s outstanding shares have now reached $38.27 million.
Let’s determine the extent of company efficiency that accounts for 173 employees. In terms of profitability, gross margin is 99.12%, operating margin of -435.19%, and the pretax margin is -340.68%.
ITeos Therapeutics Inc (ITOS) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of ITeos Therapeutics Inc is 13.52%, while institutional ownership is 84.56%. The most recent insider transaction that took place on Nov 19 ’24, was worth 38,635. In this transaction Chief Financial Officer of this company bought 5,000 shares at a rate of $7.73, taking the stock ownership to the 65,429 shares.
ITeos Therapeutics Inc (ITOS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -3.58% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.43% during the next five years compared to -34.39% drop over the previous five years of trading.
ITeos Therapeutics Inc (NASDAQ: ITOS) Trading Performance Indicators
Here are ITeos Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 14.13. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.23, a number that is poised to hit -0.88 in the next quarter and is forecasted to reach -3.43 in one year’s time.
Technical Analysis of ITeos Therapeutics Inc (ITOS)
Looking closely at ITeos Therapeutics Inc (NASDAQ: ITOS), its last 5-days average volume was 2.68 million, which is a jump from its year-to-date volume of 0.5 million. As of the previous 9 days, the stock’s Stochastic %D was 49.20%. Additionally, its Average True Range was 0.56.
During the past 100 days, ITeos Therapeutics Inc’s (ITOS) raw stochastic average was set at 82.43%, which indicates a significant increase from 71.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.87% in the past 14 days, which was higher than the 60.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.65, while its 200-day Moving Average is $9.38. However, in the short run, ITeos Therapeutics Inc’s stock first resistance to watch stands at $8.33. Second resistance stands at $8.80. The third major resistance level sits at $9.11. If the price goes on to break the first support level at $7.55, it is likely to go to the next support level at $7.24. Should the price break the second support level, the third support level stands at $6.77.
ITeos Therapeutics Inc (NASDAQ: ITOS) Key Stats
With a market capitalization of 300.45 million, the company has a total of 38,274K Shares Outstanding. Currently, annual sales are 35,000 K while annual income is -134,410 K. The company’s previous quarter sales were 0 K while its latest quarter income was -34,610 K.
